MCID: MYL069
MIFTS: 83

Myeloma, Multiple

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Myeloma, Multiple

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 57 38 40
Multiple Myeloma 57 38 12 76 53 25 59 75 37 29 13 6 43 44 15 73
Plasma Cell Myeloma 12 53 59 55
Medullary Plasmacytoma 25 59 73
Plasma Cell Dyscrasia 53 25 73
Myelomatosis 53 25 59
Multiple Myeloma, Resistance to 57 6
Primary Systemic Amyloidosis 59 73
Primary Amyloidosis 59 73
Kahler's Disease 25 59
Kahler Disease 53 25
Multiple Myeloma, Susceptibility to 57
Immunoglobulin Deposition Disease 73
Systemic Al Amyloidosis 59
Light-Chain Amyloidosis 59
Kahler-Bozzolo Disease 25
Plasma Cell Neoplasm 73
Plasma Cell Myelomas 25
Myeloma - Multiple 53
Al Amyloidosis 59
Mm 75

Characteristics:

Orphanet epidemiological data:

59
primary systemic amyloidosis
Inheritance: Not applicable;
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
myeloma, multiple:
Inheritance somatic mutation autosomal recessive inheritance


Classifications:



Summaries for Myeloma, Multiple

NIH Rare Diseases : 53 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS). Treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting.

MalaCards based summary : Myeloma, Multiple, also known as multiple myeloma, is related to plasma cell leukemia and melanoma. An important gene associated with Myeloma, Multiple is CCND1 (Cyclin D1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Cytokine Signaling in Immune system. The drugs Aredia and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are osteopenia and pathologic fracture

OMIM : 57 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500)

UniProtKB/Swiss-Prot : 75 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

MedlinePlus : 43 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include Bone pain, often in the back or ribs Broken bones Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

Genetics Home Reference : 25 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Wikipedia : 76 Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood... more...

Related Diseases for Myeloma, Multiple

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 34.4 CCND1 FGFR3
2 melanoma 32.5 BRAF CDK4 MALAT1 MIR15A MIR181A2 MIR19A
3 adenocarcinoma 32.3 BRAF CCND1 CDK4 FGFR3 HRAS TP53
4 leukemia, chronic lymphocytic 32.2 BRAF CCND1 HRAS MIR106B MIR15A MIR181A2
5 poems syndrome 12.0
6 colorectal cancer 11.6 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
7 squamous cell carcinoma, head and neck 11.6 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
8 lung cancer susceptibility 3 11.6 BRAF CCND1 CDK4 FGFR3 HRAS MALAT1
9 glioblastoma 11.6 BRAF CCND1 CDK4 HRAS IDH2 MALAT1
10 bladder urothelial carcinoma 11.6 BRAF CCND1 FGFR3 HRAS MALAT1 NRAS
11 cell type cancer 11.6 CCND1 CDK4 HRAS NRAS TP53
12 hepatocellular carcinoma 11.6 CCND1 CDK4 HRAS IDH2 MALAT1 MIR106B
13 renal cell carcinoma, papillary, 1 11.6 BRAF FGFR3 HRAS NRAS TP53
14 glioma 11.6 BRAF CCND1 CDK4 IDH2 MALAT1 MIR15A
15 lung cancer 11.6 BRAF CCND1 CDK4 HRAS MALAT1 MIR15A
16 pilocytic astrocytoma 11.6 BRAF CDK4 HRAS PTPN11 TP53
17 skin melanoma 11.6 BRAF CDK4 HRAS NRAS TP53
18 nasopharyngeal carcinoma 11.6 CCND1 CDK4 HRAS MALAT1 NRAS TP53
19 liver angiosarcoma 11.6 CDK4 HRAS NRAS TP53
20 brain cancer 11.6 BRAF HRAS IDH2 MIR25 NRAS TP53
21 leukemia, acute myeloid 11.6 HRAS IDH2 MALAT1 MIR181A2 NRAS PTPN11
22 pancreatic cancer 11.6 CCND1 CDK4 HRAS MALAT1 MIR15A MIR181A2
23 squamous cell carcinoma 11.6 BRAF CCND1 FGFR3 HRAS MALAT1 TP53
24 light chain deposition disease 11.6
25 melanoma, cutaneous malignant 1 11.6 CDK4 HRAS NRAS TP53
26 ovarian serous cystadenocarcinoma 11.6 BRAF HRAS NRAS TP53
27 adamantinoma of long bones 11.6 BRAF CCND1 CDK4 MALAT1 TP53
28 thyroid cancer 11.6 BRAF CCND1 HRAS MALAT1 NRAS TP53
29 lung squamous cell carcinoma 11.6 BRAF FGFR3 HRAS PTPN11 TP53
30 differentiated thyroid carcinoma 11.6 BRAF HRAS NRAS TP53
31 spitz nevus 11.6 BRAF HRAS TP53
32 respiratory system cancer 11.6 CCND1 HRAS MALAT1 TP53
33 gastric adenocarcinoma 11.6 BRAF CCND1 HRAS NRAS TP53
34 bladder cancer 11.5 CCND1 CDK4 FGFR3 HRAS MALAT1 TP53
35 prostate cancer 11.5 CCND1 CDK4 HRAS MALAT1 MIR106B MIR15A
36 gastrointestinal system cancer 11.5 CCND1 HRAS MALAT1 TP53
37 meningeal melanomatosis 11.5 HRAS NRAS TP53
38 monoclonal gammopathy of uncertain significance 11.5
39 myelodysplastic myeloproliferative cancer 11.5 HRAS NRAS PTPN11
40 nevus, epidermal 11.5 FGFR3 HRAS NRAS
41 small cell sarcoma 11.5 CDK4 NRAS TP53
42 noonan syndrome 1 11.5 BRAF HRAS NRAS PTPN11
43 melanoma, uveal 11.5 BRAF CDK4 MALAT1 NRAS
44 lynch syndrome 11.5 BRAF CCND1 LIG4 TP53
45 ovarian cancer 11.5 BRAF CCND1 CDK4 MALAT1 MIR106B MIR15A
46 leopard syndrome 11.5 BRAF HRAS PTPN11
47 mantle cell lymphoma 11.5 CCND1 CDK4 MALAT1 TP53
48 cholangiocarcinoma 11.5 CCND1 HRAS IDH2 MALAT1 TP53
49 cervical cancer 11.5 CCND1 FGFR3 HRAS MALAT1 TP53
50 embryonal sarcoma 11.5 CDK4 MALAT1 TP53

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple

Symptoms & Phenotypes for Myeloma, Multiple

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
multiple myeloma

Laboratory Abnormalities:
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)
paraproteinemia


Clinical features from OMIM:

254500

Human phenotypes related to Myeloma, Multiple:

59 32 (show top 50) (show all 82)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000938
2 pathologic fracture 59 32 hallmark (90%) Very frequent (99-80%) HP:0002756
3 nephrotic syndrome 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
4 nephropathy 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
5 anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001903
6 acute kidney injury 59 32 frequent (33%) Frequent (79-30%) HP:0001919
7 hyperproteinemia 59 32 frequent (33%) Frequent (79-30%) HP:0002152
8 bone pain 59 32 frequent (33%) Frequent (79-30%) HP:0002653
9 increased igg level 59 32 frequent (33%) Frequent (79-30%) HP:0003237
10 elevated serum creatinine 59 32 frequent (33%) Frequent (79-30%) HP:0003259
11 generalized muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0003324
12 decreased antibody level in blood 59 32 frequent (33%) Frequent (79-30%),Occasional (29-5%) HP:0004313
13 fatigue 59 32 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
14 abnormality of the bladder 59 32 occasional (7.5%) Occasional (29-5%) HP:0000014
15 tall stature 59 32 occasional (7.5%) Occasional (29-5%) HP:0000098
16 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
17 spinal cord compression 59 32 occasional (7.5%) Occasional (29-5%) HP:0002176
18 vertebral compression fractures 59 32 occasional (7.5%) Occasional (29-5%) HP:0002953
19 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
20 increased iga level 59 32 occasional (7.5%) Occasional (29-5%) HP:0003261
21 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
22 abnormality of vitamin b12 metabolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0004341
23 functional abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0012719
24 splenomegaly 59 32 very rare (1%) Very rare (<4-1%) HP:0001744
25 pleural effusion 59 32 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
26 lymphadenopathy 59 32 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
27 multiple myeloma 59 32 Frequent (79-30%) HP:0006775
28 renal insufficiency 59 Frequent (79-30%)
29 proteinuria 59 Frequent (79-30%)
30 enlarged kidney 59 Frequent (79-30%)
31 macroglossia 59 Occasional (29-5%)
32 xerostomia 59 Occasional (29-5%)
33 hematuria 59 Occasional (29-5%)
34 goiter 59 Occasional (29-5%)
35 adrenal insufficiency 59 Occasional (29-5%)
36 purpura 59 Occasional (29-5%)
37 keratoconjunctivitis sicca 59 Occasional (29-5%)
38 polyneuropathy 59 Occasional (29-5%)
39 hepatomegaly 59 Frequent (79-30%)
40 congestive heart failure 59 Frequent (79-30%)
41 hypertrophic cardiomyopathy 59 Very frequent (99-80%)
42 bradycardia 59 Occasional (29-5%)
43 asplenia 59 Occasional (29-5%)
44 constipation 59 Frequent (79-30%)
45 malabsorption 59 Occasional (29-5%)
46 dyspnea 59 Frequent (79-30%)
47 gastrointestinal hemorrhage 59 Occasional (29-5%)
48 autonomic dysregulation 59 Occasional (29-5%)
49 gastrointestinal dysmotility 59 Occasional (29-5%)
50 osteoarthritis 59 Occasional (29-5%)

GenomeRNAi Phenotypes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CDK4 FGFR3 HRAS NRAS PTPN11
2 Reduced mammosphere formation GR00396-S 9.17 BRAF CCND1 CDK4 HRAS IDH2 NRAS

MGI Mouse Phenotypes related to Myeloma, Multiple:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.91 LIG4 NRAS PTPN11 TP53 BRAF CCND1
2 craniofacial MP:0005382 9.87 BRAF CCND1 FGFR3 HRAS NRAS PTPN11
3 integument MP:0010771 9.76 BRAF CCND1 CDK4 FGFR3 HRAS NRAS
4 neoplasm MP:0002006 9.65 BRAF CCND1 CDK4 FGFR3 HRAS IDH2
5 pigmentation MP:0001186 9.02 BRAF CDK4 NRAS PTPN11 TP53

Drugs & Therapeutics for Myeloma, Multiple

FDA approved drugs:

(show all 17)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
2
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
3
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
4
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
5
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
6
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
7
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
8
Pomalyst 18 49 POMALIDOMIDE Celgene February 2013
9
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
10
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
11
Subsys 18 FENTANYL Insys Therapeutics January of 2012
12
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
13
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
14
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
15
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
16
Adempas 18 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
17
Vibativ 18 * TELAVANCIN * TELAVANCIN HYDROCHLORIDE Theravance June 2013

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 692)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
9
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
12
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
13
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
14
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
15
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
16
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
17
Phentolamine Approved Phase 4 50-60-2 5775
18
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
19 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
20
Liraglutide Approved Phase 4 204656-20-2 44147092
21
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
22
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
23
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
24
Pirarubicin Investigational Phase 4 72496-41-4
25 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
36 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 JM 3100 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2509)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
6 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
9 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
10 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
12 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
13 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
15 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
16 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
17 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
19 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
20 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
21 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
22 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
23 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
24 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
25 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Enrolling by invitation NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
26 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
27 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
28 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
29 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
30 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
31 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
32 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
33 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
34 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
35 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
36 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
37 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
38 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. Unknown status NCT01908621 Phase 3 G-CSF (filgrastim);Cytosine arabinoside + G-CSF (filgrastim)
39 A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Unknown status NCT01470131 Phase 3 masitinib 6 mg/kg/day;placebo
40 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
41 MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation Unknown status NCT00256776 Phase 3 Velcade (Bortezomib);Thalidomide;Dexamethasone
42 Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Unknown status NCT02066454 Phase 3 Apixaban
43 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
44 Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy Unknown status NCT00571168 Phase 3 Emend;Placebo
45 VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) Unknown status NCT01134484 Phase 3 Velcade;Thalidomide;Dexamethasone
46 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
47 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
48 Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
49 Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
50 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Myeloma, Multiple

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 29 CCND1 LIG4

Anatomical Context for Myeloma, Multiple

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloma, Multiple:

19
The Plasma Cells In Bone Marrow

MalaCards organs/tissues related to Myeloma, Multiple:

41
Bone, Bone Marrow, T Cells, B Cells, Testes, Myeloid, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Myeloma, Multiple

Articles related to Myeloma, Multiple:

(show top 50) (show all 4844)
# Title Authors Year
1
Dysphagia due to macroglossia in a patient with amyloidosis associated with multiple myeloma: A case report. ( 29889980 )
2018
2
MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. ( 28905994 )
2018
3
Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. ( 29761833 )
2018
4
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. ( 29978498 )
2018
5
Multiple myeloma causing interstitial pulmonary infiltrates and soft-tissue plasmacytoma. ( 29977785 )
2018
6
Seronegative alveolar echinococcosis in a patient with multiple myeloma. ( 29425710 )
2018
7
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. ( 29523615 )
2018
8
Drug response prediction in high-risk multiple myeloma. ( 29122646 )
2018
9
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. ( 29158114 )
2018
10
IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. ( 28786198 )
2018
11
DANFIN functions as an inhibitor of transcription factor NF-I_B and potentiates the antitumor effect of bortezomib in multiple myeloma. ( 29284118 )
2018
12
IgA kappa light and heavy chain deposition disease in multiple myeloma. ( 29808912 )
2018
13
Membrane translocation of Bruton kinase in multiple myeloma cells is associated with osteoclastogenic phenotype in bone metastatic lesions. ( 29480835 )
2018
14
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. ( 29235380 )
2018
15
Systemic mastocytosis with concurrent multiple myeloma. ( 29599147 )
2018
16
Multiple myeloma cells adapted to long-exposure of hypoxia exhibit stem cell characters with TGF-I^/Smad pathway activation. ( 29309790 )
2018
17
Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. ( 29214761 )
2018
18
Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth. ( 29061667 )
2018
19
High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. ( 29031566 )
2018
20
Anti-ZIC4 associated paraneoplastic cerebellar degeneration in a patient with both diffuse large B-cell lymphoma and incidental smoldering multiple myeloma. ( 29249374 )
2018
21
Long Non-Coding RNAs in Multiple Myeloma. ( 29389884 )
2018
22
Immunohistochemical Labeling of Multiple Myeloma Oncogene 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Cutaneous Histiocytoma. ( 29444632 )
2018
23
Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. ( 28479151 )
2018
24
TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling. ( 29214775 )
2018
25
Epigenetic silencing of LPP/miR-28 in multiple myeloma. ( 28775176 )
2018
26
Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy. ( 29507277 )
2018
27
Interferon I^ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells. ( 29510136 )
2018
28
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. ( 29390932 )
2018
29
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. ( 28987930 )
2018
30
Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. ( 29706650 )
2018
31
Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. ( 29928372 )
2018
32
Successful Treatment of Recurrent Gastrointestinal Bleeding due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide - Two Birds with One Stone. ( 29911985 )
2018
33
Hypoxia-inducible KDM3A addiction in multiple myeloma. ( 29444873 )
2018
34
Age-related health care disparities in multiple myeloma. ( 28429426 )
2018
35
Late Relapse of Multiple Myeloma with Testicular Plasmacytoma after Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature. ( 29531008 )
2018
36
Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis. ( 28799843 )
2018
37
Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )
2018
38
IgM- Kappa type multiple myeloma with simultaneous gastro-esophageal involvement simulating linitis plastica. ( 29747781 )
2018
39
Generalized erythematous and scaly plaques and papules: a rare case of Rosai-Dorfman disease accompanied by multiple myeloma. ( 29924217 )
2018
40
Panoramic and skull imaging may aid in the identification of multiple myeloma lesions. ( 29274154 )
2018
41
A case of acute liver failure due to carfilzomib in multiple myeloma. ( 29969517 )
2018
42
Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma. ( 29907543 )
2018
43
Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. ( 29363041 )
2018
44
A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. ( 29032271 )
2018
45
Multiple Cranial Nerve Palsy Concomitant with Leptomeningeal Involvement in Multiple Myeloma: A Case Report and Review of Literature. ( 29951172 )
2018
46
Host-related immunodeficiency in the development of multiple myeloma. ( 28792255 )
2018
47
Amelioration of NK cell function driven by VI+24<sup>+</sup> invariant NKT cell activation in multiple myeloma. ( 29061445 )
2018
48
Epigenetic silencing of EVL/miR-342 in multiple myeloma. ( 29242101 )
2018
49
LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. ( 29501744 )
2018
50
CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. ( 29264740 )
2018

Variations for Myeloma, Multiple

ClinVar genetic disease variations for Myeloma, Multiple:

6
(show top 50) (show all 284)
# Gene Variation Type Significance SNP ID Assembly Location
1 LIG4 NM_002312.3(LIG4): c.8C> T (p.Ala3Val) single nucleotide variant protective rs1805389 GRCh37 Chromosome 13, 108863609: 108863609
2 LIG4 NM_002312.3(LIG4): c.8C> T (p.Ala3Val) single nucleotide variant protective rs1805389 GRCh38 Chromosome 13, 108211261: 108211261
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
7 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
8 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
11 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
15 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
17 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
18 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
19 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
20 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
21 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
22 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
23 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
24 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
25 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
28 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
29 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
30 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
31 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
32 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
33 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
34 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
35 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
36 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
37 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
38 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
39 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
40 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
41 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
42 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
43 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh38 Chromosome 7, 140781611: 140781611
44 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
46 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
47 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
48 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
50 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154

Copy number variations for Myeloma, Multiple from CNVD:

7 (show top 50) (show all 302)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
7 17467 1 142902432 245422432 Gain Multiple myeloma
8 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
9 20611 1 153300000 154800000 Gain EST1B Multiple myeloma
10 20700 1 1536308 6536308 Loss Multiple myeloma
11 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
12 20849 1 154800000 158800000 Gain CAPON Multiple myeloma
13 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
14 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
15 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
16 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
17 29497 1 23265113 23869113 Loss Multiple myeloma
18 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
19 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
20 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
21 31749 1 30500000 184000000 Gain Multiple myeloma
22 33943 1 50669458 53683458 Loss Multiple myeloma
23 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
24 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
25 36791 1 80821425 83677425 Loss Multiple myeloma
26 36969 1 84171854 96213854 Loss Multiple myeloma
27 37035 1 84700000 88100000 Gain Multiple myeloma
28 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
29 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
30 37525 10 30762871 30790767 Gain EST Multiple myeloma
31 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
32 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
33 41379 10 17300000 22600000 Gain and amplificati on Multiple myeloma
34 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
35 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
36 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
37 48574 11 100828925 102320925 Loss KIAA1377 Multiple myeloma
38 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
39 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
40 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
41 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
42 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
43 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
44 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
45 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
46 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
47 48584 11 100828925 102320925 Loss PORIMIN Multiple myeloma
48 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
49 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
50 49668 11 110000000 112800000 Gain POU2AF1 Multiple myeloma

Expression for Myeloma, Multiple

Search GEO for disease gene expression data for Myeloma, Multiple.

Pathways for Myeloma, Multiple

Pathways related to Myeloma, Multiple according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myeloma, Multiple according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 BRAF CCND1 FGFR3 HRAS NRAS PTPN11
2
Show member pathways
12.99 CCND1 CDK4 FGFR3 HRAS NRAS TP53
3
Show member pathways
12.81 BRAF CCND1 CDK4 HRAS NRAS PTPN11
4 12.77 BRAF FGFR3 HRAS NRAS TP53
5
Show member pathways
12.74 BRAF FGFR3 HRAS NRAS PTPN11
6
Show member pathways
12.74 BRAF CCND1 CDK4 HRAS NRAS TP53
7 12.74 BRAF CCND1 CDK4 FGFR3 HRAS NRAS
8
Show member pathways
12.73 FGFR3 HRAS NRAS PTPN11 TP53
9
Show member pathways
12.72 BRAF HRAS NRAS PTPN11 TP53
10
Show member pathways
12.65 BRAF CCND1 CDK4 FGFR3 HRAS NRAS
11
Show member pathways
12.58 CCND1 CDK4 HRAS NRAS TP53
12
Show member pathways
12.57 BRAF FGFR3 HRAS NRAS PTPN11
13
Show member pathways
12.54 BRAF CCND1 HRAS NRAS TP53
14
Show member pathways
12.49 BRAF FGFR3 HRAS NRAS TP53
15
Show member pathways
12.48 CCND1 HRAS NRAS PTPN11
16
Show member pathways
12.44 FGFR3 HRAS NRAS PTPN11
17
Show member pathways
12.44 FGFR3 HRAS NRAS TP53
18
Show member pathways
12.42 CDK4 HRAS NRAS PTPN11
19
Show member pathways
12.42 CCND1 CDK4 HRAS NRAS
20 12.41 CCND1 CDK4 HRAS NRAS TP53
21
Show member pathways
12.38 BRAF HRAS NRAS PTPN11
22
Show member pathways
12.38 BRAF CCND1 HRAS NRAS PTPN11 TP53
23
Show member pathways
12.35 CCND1 CDK4 MIR106B MIR19A TP53
24 12.27 CCND1 CDK4 HRAS NRAS TP53
25
Show member pathways
12.23 BRAF FGFR3 HRAS NRAS PTPN11
26
Show member pathways
12.18 BRAF HRAS NRAS TP53
27 12.16 BRAF CCND1 CDK4 TP53
28
Show member pathways
12.15 BRAF HRAS NRAS TP53
29
Show member pathways
12.15 BRAF HRAS NRAS PTPN11 TP53
30 12.11 CCND1 CDK4 HRAS NRAS TP53
31 12.1 BRAF CCND1 HRAS NRAS PTPN11 TP53
32
Show member pathways
12.09 BRAF CCND1 HRAS NRAS
33 12.06 BRAF HRAS NRAS TP53
34
Show member pathways
12.06 CCND1 CDK4 HRAS NRAS
35
Show member pathways
12.04 BRAF CCND1 CDK4 FGFR3
36 12 CCND1 CDK4 FGFR3 HRAS NRAS TP53
37 11.99 CCND1 HRAS NRAS TP53
38 11.98 CCND1 HRAS NRAS TP53
39 11.97 BRAF HRAS NRAS PTPN11
40 11.89 CCND1 CDK4 HRAS NRAS
41 11.87 CCND1 CDK4 TP53
42 11.84 CCND1 CDK4 TP53
43 11.84 CCND1 FGFR3 HRAS MIR106B MIR15A MIR181A2
44
Show member pathways
11.8 BRAF HRAS NRAS
45 11.71 BRAF CDK4 HRAS
46 11.68 HRAS NRAS TP53
47
Show member pathways
11.68 BRAF HRAS NRAS
48 11.68 BRAF CCND1 CDK4 HRAS NRAS TP53
49 11.65 FGFR3 HRAS NRAS TP53
50 11.64 BRAF HRAS NRAS

GO Terms for Myeloma, Multiple

Biological processes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.73 BRAF FGFR3 HRAS NRAS
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 BRAF FGFR3 HRAS PTPN11
3 Ras protein signal transduction GO:0007265 9.54 HRAS NRAS TP53
4 miRNA mediated inhibition of translation GO:0035278 9.43 MIR106B MIR15A MIR181A2
5 epidermal growth factor receptor signaling pathway GO:0007173 9.33 HRAS NRAS PTPN11
6 mitotic G1 DNA damage checkpoint GO:0031571 9.32 CCND1 TP53
7 gene silencing by miRNA GO:0035195 9.17 MIR106B MIR15A MIR181A2 MIR19A MIR25 MIR32
8 response to X-ray GO:0010165 9.13 CCND1 LIG4 TP53

Molecular functions related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.43 BRAF CDK4 FGFR3 HRAS LIG4 NRAS
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR106B MIR15A MIR181A2 MIR19A MIR25 MIR32

Sources for Myeloma, Multiple

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....